CSPC Pharmaceutical Group: Signed an exclusive licensing agreement with BeiGene for SYH2039

2024-12-13 08:30:42

On December 13, CSPC Pharmaceutical Group announced on the Hong Kong Stock Exchange that it has entered into an exclusive licensing agreement with BeiGene for the global development, manufacturing and commercialization of the group's novel methionine adenosyltransferase 2A (MAT2A) inhibitor (SYH2039) and any subsequent pharmaceutical products consisting of or containing the compound.

BeiGene

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Southwest Airlines CEO: Although Boeing still has a lot of work to do, they seem to be moving in a good direction and we are more optimistic.
                            2025-01-31

                                    White House Press Secretary Levitt: Details about the Nvidia meeting are still unclear.
                            2025-02-01

                                    Apple (AAPL.O) said the Apple Pay outage has been resolved.
                            2025-01-29

                                    Jefferies: Raised Meta Platforms (META.O) price target from $715 to $810.
                            2025-01-30

                                    Sam Altman, founder and CEO of OpenAI: OpenAI will develop specialized hardware for AI.
                            2025-02-03